mRNA vaccines for COVID-19 have put mRNA technology in the spotlight for many companies wanting to rapidly develop vaccines for infectious diseases and non-viral gene and cell therapy applications. The manufacturing process must be safe, reliable, efﬁcient, low-cost, and ﬂexible to allow on-demand production that meet regulatory requirements. To achieve successful these goals, developers will need in the early stage of their project to design a scalable manufacturing process taking advantage of single single-use technology and automation.
A well-defined product profile will help them to understand the future manufacturing scale and the challenges associated with it. Learn how to be successful in your production with a session from Catherine Jomary, PhD. at the PDA Ireland ATMP Conference.